

Advent Pharma Ltd.
Statement of Financial Position
As at September 30, 2021

Particulars	Notes	Amount in Taka	
		30-Sep-2021	30-Jun-2021
ASSETS			
NON-CURRENT ASSETS		1,287,372,139	1,257,626,287
Property, Plant and Equipment	4.00	1,217,879,453	1,227,902,159
Capital Work in Progress (Building Construction)	5.00	69,492,686	29,724,128
Right of use Assets		291,416	437,124
CURRENT ASSETS		244,380,928	261,979,334
Inventories	6.00	80,354,786	75,411,909
Trade and Other Receivable		122,345,620	114,021,998
Advances, Deposits and Pre-payments		35,288,369	29,856,397
Investment in FDR	7.00	-	40,000,000
Cash and Cash Equivalents	8.00	6,392,153	2,689,030
Total Assets		1,532,044,483	1,520,042,745
SHAREHOLDERS' EQUITY AND LIABILITIES			
SHAREHOLDERS' EQUITY		1,270,616,153	1,234,180,120
Share Capital	9.00	913,066,000	913,066,000
Retained Earnings	10.00	357,550,153	321,114,120
NON-CURRENT LIABILITIES		135,505,230	133,550,170
Long Term Borrowings - Net of Current Portion		14,233,738	14,561,946
Deferred Tax Liabilities	11.00	121,271,492	118,988,224
Liabilities for lease net of current maturity	13.00	-	-
CURRENT LIABILITIES		125,923,100	152,312,455
Current Portion of Long Term Borrowings		7,912,963	7,912,963
Payable to IPO Applicants		109,355	109,355
Short Term Borrowings		8,575,288	36,826,566
Trade and other payables		6,258,217	8,917,226
Unclaimed Dividend Account	12.00	4,117,987	6,550,487
Liabilities for Lease-current maturity	13.00	448,239	607,545
Liabilities for expenses		4,058,512	8,468,549
Liability for contribution to WPPF		33,736,600	30,508,761
Provision for Current Tax	14.00	60,705,939	52,411,003
Total Liabilities		261,428,330	285,862,625
Total Shareholders' Equity and Liabilities		1,532,044,483	1,520,042,745
Net Asset Value (NAV) per Share	22.00	13.92	13.52


Company Secretary


Chief Financial Officer


Director


Managing Director


Chairman

Dated: November 14, 2021

Place: Dhaka

Advent Pharma Ltd.
Statement of Profit or Loss and Other Comprehensive Income
For the Period ended September 30, 2021

Particulars	Notes	Amount in Taka	
		July 01, 2021 to Sept. 30, 2021	July 01, 2020 to Sept. 30, 2020
A Revenues		134,587,624	129,526,361
B Cost of Sales	15.00	(76,330,220)	(73,088,190)
C Gross Profit		58,257,404	56,438,171
Operating Expenses		(13,083,672)	(10,404,993)
D Administrative expenses	17.00	(4,737,292)	(3,965,314)
Selling & Marketing Expenses	18.00	(8,346,380)	(6,439,679)
E Operating Profit		45,173,732	46,033,178
Non Operating Expenses		(1,696,080)	(1,646,676)
F Financial Expenses	19.00	(1,696,080)	(1,646,676)
G Other Income	20.00	5,887,297	3,132,692
H Profit Before W.P.P.F		49,364,949	47,519,194
I Expenses for W.P.P.F		(2,350,712)	(2,262,819)
J Profit Before Tax		47,014,237	45,256,375
K Income Tax Expenses		(10,578,203)	(11,627,364)
Current Tax	14.00	(8,294,936)	(5,959,323)
Deferred Tax	11.00	(2,283,268)	(5,668,041)
L Net Profit After Tax		36,436,033	33,629,011
M Other Comprehensive Income		-	-
N Total Comprehensive Income		36,436,033	33,629,011
O Earnings per Share (EPS)	21.00	0.40	0.37


Company Secretary


Chief Financial Officer


Director


Managing Director


Chairman

Dated: November 14, 2021
Place: Dhaka

Advent Pharma Ltd.
Statement of Changes in Equity
For the Period ended September 30, 2021

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as on July 01, 2021	913,066,000	321,114,120	1,234,180,120
Net Profit for the period	-	36,436,033	36,436,033
Balance as on September 30, 2021	913,066,000	357,550,153	1,270,616,153

Advent Pharma Ltd.
Statement of Changes in Equity
For the Period ended September 30, 2020

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as on July 01, 2020	830,060,000	290,530,279	1,120,590,279
Net Profit for the period	-	33,629,011	33,629,011
Balance as on September 30, 2020	830,060,000	324,159,290	1,154,219,290


Company Secretary


Chief Financial Officer


Director


Managing Director


Chairman

Dated: November 14, 2021
Place: Dhaka

Advent Pharma Ltd.
Statement of Cash Flows
For the Period ended September 30, 2021

Particulars	Amount in Taka	
	July 01, 2021 to Sept. 30, 2021	July 01, 2020 to Sept. 30, 2020
A. CASH FLOWS FROM OPERATING ACTIVITIES:		
Cash Receipts from Customers & Others	132,151,299	142,375,064
Cash Paid to Suppliers	(73,411,138)	(63,975,963)
Cash paid to Employees	(10,775,445)	(9,251,625)
Cash paid to Others	(7,211,080)	(5,797,666)
Tax Paid During This period	(331,213)	(375,838)
Net cash generated from operating activities	40,422,423	62,973,972
B. CASH FLOWS FROM INVESTING ACTIVITIES:		
Paid for Acquisition of Property, Plant & Equipment	(176,040)	(60,920)
Paid for Capital Work -in- Progress (construction)	(41,568,558)	(65,163,500)
Investment in FDR	40,000,000	-
Net cash used for investing activities	(1,744,598)	(65,224,420)
C. CASH FLOWS FROM FINANCING ACTIVITIES:		
Net Received/Payment of Short Term Borrowings	(28,251,278)	2,102,446
Net Received/Payment of Long Term Borrowings	(328,208)	-
Financial Expenses Paid	(3,790,216)	(1,045,936)
Cash Dividend Paid	(2,432,500)	(2,141,382)
Lease Payment	(172,500)	(172,500)
Net cash provided by financing activities	(34,974,703)	(1,257,372)
D. Net Increase/(Decrease) in cash & cash equivalents (A+B+C)	3,703,123	(3,507,819)
E. Cash & Cash equivalents at the beginning of the period	2,689,030	6,338,662
F. Cash & Cash equivalents at the end of the period (D+E)	6,392,153	2,830,843
G. Net Operating Cash Flows Per Share	0.44	0.69

 Company Secretary	 Chief Financial Officer	 Director	 Managing Director	 Chairman
---	---	--	--	--

Dated: November 14, 2021
Place: Dhaka

Advent Pharma Limited
Notes, comprising a summary of significant accounting policies and other explanatory information
as at and for the period ended 30 Sept.-2021

1.00 Corporate History of the Reporting Entity

Advent Pharma Limited (The Company) was incorporated in Bangladesh as a Private Limited Company under The Companies Act, 1994 vide Registration No. C-65459(2951)/2007 dated 25th January, 2007. Subsequently the company was converted into Public Company Limited by share 07 May 2016. The registered office of the company and the factory is located at Plot # B50-54, BSCIC Industrial Estate, Dhamrai, Dhaka, Bangladesh.

2.00 Corporate Business

The Company is a Pharmaceutical company which is engaged in manufacturing, importing and marketing of animal health care drugs, nutritional supplements and feed additives for livestock like powder, bolus and liquid dosage forms. All products have duly been approved by Drug Administration Authority and Department of Live Stock respectively.

3.00 Basis of preparation and significant accounting policies

The financial statements of the company have been prepared on going concern assumption under historical cost convention, on accrual basis and in accordance with the International Accounting Standards (IASs), International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities and Exchange Rules 2020, the requirements of Financial Reporting Act 2015, Value Added Tax and Supplementary Duty Act 2012, Income Tax Ordinance 1984 and other laws and regulations applicable for the company.

The following International Accounting Standards were applied for the preparation of the financial statements for the period.

IAS 1	Presentation of Financial Statements
IAS 2	Inventories
IAS 7	Statement of Cash Flows
IAS 8	Accounting Policies, Changes in Accounting Estimates and Errors
IAS 10	Events after the Reporting Period
IAS 12	Income Taxes
IAS 16	Property, Plant & Equipment
IAS 19	Employee Benefits
IAS 23	Borrowing Costs
IAS 24	Related Party Disclosures
IAS 32	Financial instruments: Presentation
IAS 33	Earnings per Share
IAS 34	Interim Financial Reporting
IAS 36	Impairment of Assets
IAS 37	Provisions, Contingent Liabilities and Contingent Assets
IFRS 7	Financial Instruments: Disclosures
IFRS 8	Operating Segment
IFRS 9	Financial Instruments
IFRS 15	Revenue from Contracts with Customers
IFRS 16	Leases



		Amount in Taka	
		30-Sep-2021	30-Jun-2021
4.00	Property, Plant and Equipment		
	A. Cost		
	Opening Balance	1,381,013,653	1,214,404,201
	Add: Addition during the period	38,730	168,088,026
	Less: Disposal during the period	-	(1,478,574)
		<u>1,381,052,383</u>	<u>1,381,013,653</u>
	B. Accumulated Depreciation		
	Opening Balance	153,111,494	115,803,056
	Add: Depreciation charged during the period	10,061,436	38,168,564
	Less: Adjustment during the period	-	(860,126)
		<u>163,172,930</u>	<u>153,111,494</u>
	Written down Value (A-B)	<u>1,217,879,453</u>	<u>1,227,902,159</u>
<i>Details are shown in Annexure-A.</i>			
5.00	Capital Work In Progress (Building Construction)		
	Opening Balance	29,724,128	5,924,163
	Addition during the period	39,768,558	190,117,421
	Transfer to Factory Building	-	(166,317,456)
	Closing Balance	<u>69,492,686</u>	<u>29,724,128</u>
6.00	Inventories		
	Finished Goods (Note-24.00)	30,675,288	32,626,808
	Raw Materials (Note-24.01)	30,349,885	25,746,190
	Packing Materials (Note-24.02.01)	5,301,296	6,430,426
	Spare Parts (Note-24.02.2)	70,737	84,135
	Work In Process (Note-24.00)	13,957,580	10,524,350
		<u>80,354,786</u>	<u>75,411,909</u>
7.00	Investment in FDR		
	<u>Name of Financial Institution</u>		
	Midland Bank Ltd.	FDR No.: 0019761	
	Total	-	40,000,000
		-	<u>40,000,000</u>
8.00	Cash & Cash Equivalents		
	Cash in hand (Note-8.01)	253,796	356,016
	Cash at bank (Note-8.02)	6,138,357	2,333,014
	Total	<u>6,392,153</u>	<u>2,689,030</u>
8.01	Cash in Hand		
	Head Office	233,535	304,744
	Depots	20,261	51,272
		<u>253,796</u>	<u>356,016</u>
Cash in hand has been certified by the management of the company.			
8.02	Cash at Bank	6,138,357	2,333,014
8.02.01	Cash at Bank		
	<u>Bank Name</u>		
	Islami Bank Bangladesh Ltd.	A/C No. # 283517	56,491
	Dutch Bangla Bank Ltd.	A/C No. # 129775	249,520
	Janata Bank Ltd.	A/C No. # 10035785	143,360
	IFIC Bank Ltd.	A/C No. # 327-041	5,169,968
	IFIC Bank Ltd.	A/C No. # 327-001	107,636
	IFIC Bank Ltd.	A/C No. # 327-003	23,170
	Shahjalal Islami Bank Ltd.	A/C No. # 000-7339	106,051
	Midland Bank Ltd.	A/C No. # 000-6230	102,216
	BRAC Bank Ltd.	A/C No. # 150001	95,973
	BRAC Bank Ltd.	A/C No. # 150002	83,972
	Total	<u>6,138,357</u>	<u>2,333,014</u>
		Amount in Taka	
		30-Sep-2021	30-Jun-2021
9.00	Share Capital		
	<u>Authorized Capital :</u>		
	100,000,000 ordinary shares of Tk. 10.00 each	<u>1,000,000,000</u>	<u>1,000,000,000</u>
	<u>Issued, Subscribed & Paid-up Capital :</u>		
	830,06,000 ordinary shares of Tk. 10.00 each	<u>913,066,000</u>	<u>913,066,000</u>
	913,06,600 ordinary shares of Tk. 10.00 each		



Share holding position of Shareholders:

Category of Shareholders	No. of Share Holding		Percentage of Shareholding		Amount in Taka	
	30-Sep-21	30-Jun-21	30-Sep-21	30-Jun-21	30-Sep-21	30-Jun-21
Director & Sponsor	26,869,562	28,706,342	29.43%	31.44%	268,695,620	287,063,420
Institutional	16,416,927	17,225,306	17.98%	18.87%	164,169,270	172,253,060
Public	48,020,111	45,374,952	52.59%	49.70%	480,201,110	453,749,520
Total	91,306,600	91,306,600	100%	100%	913,066,000	913,066,000

10.00 Retained Earnings		
Balance brought forward	321,114,120	290,530,279
Add: Profit for the period	36,436,033	113,589,841
Stock Dividend	-	(83,006,000)
Balance carried forward	357,550,153	321,114,120
11.00 Deferred Tax Liabilities		
Opening Balance	118,988,224	101,428,244
Add: Provision made during the period (Note-11.01)	2,283,268	17,559,980
Closing Balance	121,271,492	118,988,224
11.01 Deferred tax liabilities as at Sept 30, 2021 is arrived as follows :		
Written Down Value of PPE as per Accounting Base	1,217,879,453	1,227,902,159
Written Down Value as per Third Schedule	(678,895,045)	(699,065,607)
Net Temporary Difference	538,984,408	528,836,552
Income Tax Rate	22.50%	22.50%
Deferred Tax Liability	121,271,492	118,988,224
Opening Deferred Tax Liability	(118,988,224)	(101,428,244)
Deferred Tax Expenses	2,283,268	17,559,980
12.00 Unclaimed Dividend Account		
Dividend Payable (2017-2018)	1,526,408	3,681,708
Dividend Payable (2018-2019)	2,589,495	2,866,695
Dividend Payable (2019-2020)	2,084	2,084
Total	4,117,987	6,550,487
13.00 Liability for Leases net of current Maturity:		
Beginning Balance	607,545	1,141,776
Add: Interest Expenses	13,194	98,269
Less: Payment	(172,500)	(632,500)
Closing Balance	448,239	607,545
Less: Liabilities for lease-current maturity	(448,239)	(607,545)
Total	-	-
14.00 Provision for Current Tax		
Opening Balance	52,411,003	49,369,509
Add: Provision for tax during the period (Note-14.01)	8,294,936	3,041,494
Total	60,705,939	52,411,003
14.01 Provision for Tax during the period		
(A) Regular		
Accounting Profit before Tax	47,014,237	134,191,315
Add: Other Inadmissible Allowances		
Accounting Depreciation	10,061,436	38,168,564
Other Income	(5,887,297)	(11,809,104)
Less: Items for Separate Consideration		
Depreciation as per 3rd Schedule	(20,209,292)	(161,474,538)
Total Taxable Income	30,979,084	(923,763)
Rate	22.50%	22.50%
Total Tax Expenses/Current Tax	6,970,294	(207,847)
Tax on other income	1,324,642	2,657,048
Total Tax Payable	8,294,936	2,449,201
(B) Minimum Tax		
Revenue from Sales	134,587,624	495,106,639
Other Income	5,887,297	11,809,104
Total Revenue	140,474,921	506,915,743
Rate of Tax	0.60%	0.60%
Minimum Tax	842,850	3,041,494
(C) Advance Tax	331,213	2,397,065
Provision for the Year (whichever is Higher)	8,294,936	3,041,494



	July 01, 2021 to Sept 30, 2021	July 01, 2020 to Sept 30, 2020
15.00 Cost of Sales		
Raw Materials Consumed	61,158,673	58,817,479
Manufacturing Overhead (Note-16.00)	17,011,715	15,261,236
	78,170,388	74,078,715
Add: Opening Work in process	10,524,350	14,402,451
Less: Closing Work in process	(13,957,580)	(13,802,451)
Cost of Goods manufactured	74,737,158	74,678,715
Add: Opening stock of finished Goods	32,626,808	24,923,097
Cost of Goods Available for Sale	107,363,966	99,601,812
Less: Closing stock of finished Goods	(30,675,288)	(26,225,405)
Less: Sample Distribution	(358,458)	(288,217)
Cost of Sales	76,330,220	73,088,190

16.00 Manufacturing Overhead		
Wages and Salary	2,992,165	2,474,746
Festival Bonus	426,900	238,388
Overtime	241,520	-
Packaging Materials Consumed	2,296,635	2,199,251
Spare Parts Consumed	178,316	204,680
Repair & Maintenance	98,319	163,561
Electricity Bill (Factory)	416,246	456,514
Disel & Fuel	29,900	44,200
Electric & Sanitary Goods	22,545	16,271
Fire Insurance Premium	43,523	43,523
Canteen Expenses	485,536	350,448
Laboratory Expenses	42,500	14,250
Cleaning & Washing	23,663	15,821
Internet bill	7,500	12,000
Mobile & Telephone bill	8,900	8,000
Uniform	32,420	49,790
Depreciation (Annexure-A)	9,665,127	8,969,793
Total	17,011,715	15,261,236

17.00 Administrative Expenses		
Salary & Allowance	2,195,250	2,063,250
Director Remuneration (Note # 25.01)	300,000	300,000
Conveyance	31,575	25,035
Subscription, Gift & Donation	26,300	17,700
Festival Bonus	299,125	148,375
Board meeting attendance fees (Note # 25.01)	45,000	45,000
Cleaning & Sanitation	14,667	12,098
Electricity Bill	65,734	73,599
Entertainment	50,667	64,678
Garage Rent	5,400	5,400
Legal, License & Renewal & Professional fee	326,081	112,305
Research & Product Development	-	4,500
Miscellaneous Expense	468,071	162,440
Newspaper & Magazine	640	-
Postage, Stamps & Courier	850	5,595
Printing & Stationery	41,325	44,616
Office Maintenance	56,350	47,535
Vehicle Repair & Maintenance	45,705	21,315
Fuel & Gas	75,856	55,676
Telephone & Mobile	48,985	64,382
Internet bill	27,000	27,000
Audit Fees Including VAT	57,500	86,250
Interest expenses on the Lease Liability	13,194	31,124
Depreciation Charge for the Right-of-Use Asset	145,708	145,708
Depreciation (Annexure-A)	396,309	401,733
Total	4,737,292	3,965,314



	July 01, 2021 to Sept 30, 2021	July 01, 2020 to Sept 30, 2020
18.00 Selling & Marketing Expenses		
Salary & Allowance	3,760,550	3,326,133
Travelling & Conveyance	865,600	744,900
Festival Bonus	382,485	224,158
Advertisement	9,106	22,800
Marketing Promotion	1,186,124	207,964
Distribution Cost	1,784,057	1,625,507
Sample Distribution	358,458	288,217
Total	8,346,380	6,439,679
19.00 Financial Expenses		
Bank Charges	118,697	15,777
Interest on Loan	700,256	1,150,646
Interest on W.P.P.F used	877,127	488,253
Total	1,696,080	1,646,676
20.00 Other Income		
Interest on FDR	1,050,000	1,700,000
Sales of Wastage	89,510	65,647
Toll Manufacturing Income	4,747,787	1,367,045
Total	5,887,297	3,132,692



21.00 Earnings Per Share

Basic Earnings per Share
Profit after tax
Weighted average number of ordinary shares outstanding
Basic Earnings per Share

Quarterly Product	
30-Sep-2021	30-Sep-2020
36,436,033	33,629,011
91,306,600	91,306,600
0.40	0.37

As there is no shares under Option, Basic & Diluted earnings per share are same for the period. This has been calculated in compliance with the requirement of IAS 33 Earnings per share. EPS is the basic earnings dividing by the weighted average number of ordinary shares outstanding at the end of the period.

21.01 Calculation of Weighted Average Number of Shares

Particulars	Share Numbers	Outstanding Period	Length in Days	Daily Product	Yearly Product (Weighted Average)	
					30-Sep-2021	30-Sep-2020
Shares at beginning	91,306,600	July-21 to Sept.-21	92	8,400,207,200	91,306,600	83,006,000
Stock Dividend-2020 @ 10%					-	8,300,600
Total	91,306,600			8,400,207,200	91,306,600	91,306,600

22.00 Net Asset Value (NAV) per Share

Total Asset
Less: Total outside Liability
Net Asset
Number of ordinary shares outstanding
Net Assets Value (NAV) per Share

30-Sep-2021	30-Jun-2021
1,532,044,483	1,520,042,745
261,428,330	285,862,626
1,270,616,153	1,234,180,119
91,306,600	91,306,600
13.92	13.52

23.00 Net Operating Cash Flows per Share(NOCFPS)

Net Cash Generated From Operating Activities
Weighted Average Number of Shares Outstanding
Net Operating Cash Flows per Share(NOCFPS)

30-Sep-2021	30-Sep-2020
40,422,423	62,973,972
91,306,600	91,306,600
0.44	0.69

24.00 Reconciliation of Net Profit with Cash flows from Operating Activities:

	30-Sep-2021	30-Sep-2020
Profit before Tax	47,014,237	45,256,375
Adjustment for:		
Depreciation on property, plant and equipment	10,061,436	9,371,526
Adjustment for depreciation of the Right Use of Assets	145,708	145,708
Interest expenses on Lease	13,194	31,124
Financial Expenses	1,696,080	1,646,676
	58,930,655	56,451,409
(Increase)/Decrease in Accounts Receivable	(8,323,622)	9,716,011
(Increase)/Decrease in Inventory	(4,942,877)	(967,897)
Increase/(Decrease) in Trade and Other Payables	(2,521,699)	(1,742,088)
Decrease/(Increase) in Advance, Deposit & Prepayments	(3,300,759)	(547,024)
Increase/(Decrease) in Liabilities for Expenses	(1,438,774)	(1,823,420)
(Increase)/Decrease in Liability for contribution to W.P.P.F	2,350,712	2,262,819
	40,753,636	63,349,810
Less: Income Tax Paid	(331,213)	(375,838)
Net Cash Generated from Operating Activities	40,422,423	62,973,972

25.00 Related parties Transaction:

As per International Accounting standards IAS 24 Related Party Disclosures, Parties are considered to be related if one of the party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decision.

25.01 As per paragraph 17 of IAS 24: Disclosure of key management personnel compensation.

a) Short-term employee benefits :

The amount of transaction for remuneration and board meeting fee during the year from 1st July 2021 to 30 th September 2021 are as follows:

Name	Designation	Remuneration	Board meeting fee
Asif Iqbal Chowdhury	Chairman	-	5,000
Faria Binta Alam	Managing Director	300,000	5,000
Wajhi Ahmed	Director	-	5,000
Kazi Rina Alam	Director	-	5,000
Md. Tazul Islam	Director	-	5,000
Mohammad Towhidul Islam	Nominee Director	-	5,000
Dr. Khandaker Sagir Ahmed	Nominee Director	-	5,000
Mohammed Salim	Independent Director	-	5,000
Sheikh Karimuzzaman	Independent Director	-	5,000
Total		300,000	45,000

b) Post employment benefits: Nil

c) Other long term benefits: Nil

d) Termination benefits: Nil

e) Share-based payment: Nil

26.00 Significant Deviation

Advent Pharma Ltd. is a veterinary medicine producer. During the period our sales has increased comparative to previous period . For this reason net profit after tax and Earnings Per Share has increased. Net operating cash flow per share has decreased due to increase of accounts receivable proportionately from previous period and increase of payment to suppliers, employees and others.



Advent Pharma Ltd.
Schedule of Property, Plant and Equipment
As at September 30, 2021

Annexure-A
(Amount in Taka)

Particulars	Cost			Depreciation				Written down value as on 30-Sept-2021
	Balance as on 01-July-2021	Addition during the Period	Disposal during the Period	Balance as on 30-Sept-2021	Charged during the Period	Adjustment during the Period	Balance as on 30-Sept-2021	
Land	3,783,816	-	-	3,783,816	-	-	-	3,783,816
Land Development	9,454,530	-	-	9,454,530	52,732	-	1,070,117	8,384,413
Factory Building	925,159,750	-	-	925,159,750	5,449,482	-	58,692,089	866,467,661
Plant & Machinery	273,073,384	10,750	-	273,084,134	2,722,700	-	57,980,123	215,104,011
Sub-Station	6,694,722	-	-	6,694,722	89,740	-	3,194,871	3,499,851
Motor Vehicle	6,158,982	-	-	6,158,982	127,683	-	2,881,781	3,277,201
Furniture & Fixture	8,126,555	23,580	-	8,150,135	128,118	-	3,134,333	5,015,802
Solar Panel	2,004,740	-	-	2,004,740	27,982	-	913,437	1,091,303
Generator	627,520	-	-	627,520	6,534	-	372,681	254,839
Air Conditioner	4,254,120	-	-	4,254,120	40,011	-	1,093,276	3,160,844
Office Equipment	6,501,413	4,400	-	6,505,813	100,497	-	2,582,035	3,923,778
HVAC System	44,536,240	-	-	44,536,240	432,656	-	10,356,456	34,179,784
Laboratory Equipment	51,378,630	-	-	51,378,630	500,056	-	11,874,194	39,504,436
Product Development Equipment	20,725,781	-	-	20,725,781	202,014	-	4,766,667	15,959,114
ETP	18,488,470	-	-	18,488,470	180,394	-	4,237,348	14,251,122
Books & Journals	45,000	-	-	45,000	837	-	23,522	21,478
Total	1,381,013,653	38,730	-	1,381,052,383	10,061,436	-	163,172,930	1,217,879,453

Allocation of Depreciation:

Administrative cost	396,309
Factory cost	9,665,127
Total	10,061,436



Advent Pharma Ltd.
Notes to the Financial Statements
As at September 30, 2020

Annexure-A
(Amount in Taka)

Particulars	Cost			Depreciation				Written down value as on 30-Sept-2020
	Balance as on 01-July-2020	Addition during the Period	Disposal during the Period	Balance as on 30-Sept-2020	Rate of Dep.	Charged during the Period	Adjustment during the Period	Balance as on 30-Sept-2020
Land	3,783,816	-	-	3,783,816	0%	-	-	3,783,816
Land Development	9,454,530	-	-	9,454,530	2.5%	54,084	-	8,599,398
Factory Building	758,842,294	-	-	758,842,294	2.5%	4,527,517	-	38,967,066
Plant & Machinery	273,035,384	-	-	273,035,384	5%	2,865,508	-	46,660,266
Sub-Station	6,694,722	-	-	6,694,722	10%	99,711	-	2,805,998
Motor Vehicle	6,097,576	-	-	6,097,576	15%	108,846	-	3,303,866
Furniture & Fixture	8,059,885	50,920	-	8,110,805	10%	140,926	-	2,580,761
Solar Panel	2,004,740	-	-	2,004,740	10%	31,091	-	792,181
Generator	627,520	-	-	627,520	10%	7,260	-	344,366
Air Conditioner	4,254,120	-	-	4,254,120	5%	42,117	-	926,916
Office Equipment	6,431,313	5,200	-	6,436,513	10%	109,844	-	2,150,854
HVAC System	44,536,240	-	-	44,536,240	5%	455,427	-	8,557,520
Laboratory Equipment	51,322,810	4,800	-	51,327,610	5%	525,677	-	9,795,924
Product Development Equipment	20,725,781	-	-	20,725,781	5%	212,646	-	3,926,713
ETP	18,488,470	-	-	18,488,470	5%	189,888	-	3,487,288
Books & Journals	45,000	-	-	45,000	15%	984	-	19,731
Total	1,214,404,201	60,920	-	1,214,465,121		9,371,526	-	125,174,582
								1,089,290,539

Allocation of Depreciation:

Administrative cost	401,733
Factory cost	8,969,793
Total	9,371,526

